Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Health Canada Issues Notice of Compliance for Gilead's Single Tablet Regimen Genvoya(TM) (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Canada NewsWire December 7, 2015

European Medicines Agency Validates Gilead's Marketing Application for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for the Treatment of Hepatitis C

Business Wire December 4, 2015

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, December 1

Business Wire November 24, 2015

European Commission Grants Marketing Authorization for Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Business Wire November 23, 2015

Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia

Business Wire November 16, 2015

Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies

Business Wire November 14, 2015

Gilead Presents New Data at The Liver Meeting 2015

Business Wire November 14, 2015

U.S. FDA Approves New Indications for Harvoni®, Gilead's Once-Daily Single Tablet Regimen for Chronic Hepatitis C

Business Wire November 12, 2015

Gilead Sciences to Present at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10

Business Wire November 9, 2015

Genvoya, new four in one daily HIV pill made by Gilead Sciences, wins approval by FDA

Canadian Press November 6, 2015

U.S. Food and Drug Administration Approves Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Business Wire November 5, 2015

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C

Business Wire October 28, 2015

Gilead Sciences Announces Fourth Quarter 2015 Dividend

Business Wire October 27, 2015

Gilead Sciences Announces Third Quarter 2015 Financial Results

Business Wire October 27, 2015

Biotech ETFs: Buy, Buy, Buy?

Benzinga.com  October 27, 2015

Gilead Announces Phase 3 Results for Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), an Investigational Once-Daily Single Tablet Regimen for HIV

Business Wire October 22, 2015

Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease

Business Wire October 21, 2015

Gilead Sciences to Release Third Quarter 2015 Financial Results on Tuesday, October 27, 2015

Business Wire October 20, 2015

U.S. Food and Drug Administration Approves New Treatment Combination of Gilead's Letairis® with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)

Business Wire October 2, 2015

European CHMP Adopts Positive Opinion for Gilead's Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for the Treatment of HIV

Business Wire September 25, 2015